In today's ACT Brief, we examine why transparency in complex trial designs is essential for data confidence, how protocol structure—not operational effort—determines recruitment success, and the FDA's ...

Two pivotal Phase 3 trials of Haduvio are expected to launch this year and, if positive, may support applications seeking its ...

MANCHESTER, UNITED KINGDOM, March 10, 2026 /EINPresswire.com/ -- Monument Therapeutics, a stratified medicine company, ...

Understand the impact of IND delays on biotechnology companies and how they affect early-stage development and funding.

Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions ...

Callan JMB will Provide Independent Manufacturing Oversight and Governance as lodonal™ Undergoes Clinical Trials for Underserved Patient Population ...

Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled ...

Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering ...

The U.S. Senate has a plan to improve drug development for rare disease patients. The exit of controversial CBER chief Vinay Prasad will help clear the path.

A new study in the Journal of Neurology offers critical longitudinal insights into how symptoms and functional impacts evolve for individuals with early Parkinson's disease (PD). Led by Jamie Adams, M ...

Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need - - QRX003 lotion (4%) currently being ...

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against the background of ongoing funding challenges and ever-increasing drug ...